Bellecapital International Ltd. Has $15.62 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

Bellecapital International Ltd. increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.9% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 27,779 shares of the biopharmaceutical company’s stock after purchasing an additional 2,276 shares during the period. Regeneron Pharmaceuticals accounts for approximately 2.5% of Bellecapital International Ltd.’s holdings, making the stock its 16th largest position. Bellecapital International Ltd.’s holdings in Regeneron Pharmaceuticals were worth $15,619,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in REGN. Activest Wealth Management lifted its holdings in Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 21 shares during the last quarter. Saudi Central Bank acquired a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at $27,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at about $31,000. Traub Capital Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $38,000. Finally, Berbice Capital Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 300.0% during the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 60 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on REGN shares. BMO Capital Markets increased their price target on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a report on Thursday, December 4th. Hsbc Global Res raised Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 24th. Canaccord Genuity Group lifted their price target on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a report on Thursday, December 4th. Royal Bank Of Canada boosted their price target on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a research note on Wednesday, October 29th. Finally, Raymond James Financial upgraded Regeneron Pharmaceuticals to a “moderate buy” rating in a research report on Tuesday, September 2nd. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $779.45.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, VP Jason Pitofsky sold 431 shares of the stock in a transaction on Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the transaction, the vice president directly owned 4,233 shares in the company, valued at approximately $2,757,503.19. This represents a 9.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Christine A. Poon sold 6,500 shares of the firm’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the sale, the director directly owned 2,352 shares in the company, valued at approximately $1,538,843.04. This trade represents a 73.43% decrease in their position. The SEC filing for this sale provides additional information. 7.02% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $784.97 on Friday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $792.77. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. The stock’s 50-day simple moving average is $703.50 and its 200 day simple moving average is $610.25. The firm has a market capitalization of $82.50 billion, a PE ratio of 18.80, a price-to-earnings-growth ratio of 2.26 and a beta of 0.37.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. During the same quarter in the previous year, the firm earned $12.46 earnings per share. The business’s quarterly revenue was up .9% on a year-over-year basis. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, December 5th. Shareholders of record on Thursday, November 20th were paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend was Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is presently 8.43%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.